Oxford spinout OMass has pivoted from offering consulting services to developing its own drugs after closing a series A round backed by Oxford Sciences Innovation.

Ireland’s Comptroller and Auditor General has highlighted issues in a Waterford Institute of Technology licensing deal that garnered low returns when the spinout in question was acquired.

Rostock-founded 3D printer maker Aim3D has secured money from investors including Brose ahead of the launch of its first product in spring 2019.

Ping An has led a $47.3m investment in Finleap through its Global Voyager Fund, joining a list of shareholders that already included Hannover Re and Signal Iduna.

Novartis Venture Fund returned to reinvest in inflammatory disease drug developer Inflazome as part of its $45.6m series B round.

The biopharmaceutical spinout of University of Veterinary Medicine Vienna is issuing 400,000 shares in an initial public offering that is set to fetch between $34m and $41m.

Inflammatory disease drug developer Inflazome, based on research at University of Queensland and Trinity College Dublin, has added $45.6m in series B capital to its coffers.

John Lonsdale will oversee a new enterprise services team at Edinburgh Innovations tasked with matters including oversight of a local scheme targeting the formation of 400 data-orientated startups.

Frontier IP sold $3.2m through a placement to new and existing backers as it announced its portfolio value had risen 34% year-on-year.

Dundee spinout Kinetic Discovery has been picked up by its peer Exscientia in a deal consolidating the equity of Frontier IP, which held stakes in both drug discovery companies.